Veralox Therapeutics is a startup currently headquartered at the Frederick Innovation Technology Center, Inc. (FITCI) in Frederick, Maryland. As a small molecule therapeutics company focused on developing medicines targeting the arachidonic acid pathway, they have two drug products in development for the treatment of a rare blood disorder known as heparin-induced thrombocytopenia and thrombosis and Type 1 Diabetes.
The BioBuzz team recently caught up with Veraloxs CEO Dr. Jeff Strovel, who spoke about the genesis of Veralox, its advancing pipeline, the companys recent milestones and its outlook for the future.
Tell our audience a bit about the founding of Veralox Therapeutics
Ill never forget the day a trusted colleague, David Maloney, called me when I was driving back to my office. He told me he had been working to develop a clinical candidate that selectively targeted the arachidonic acid (AA) pathway through inhibition of a protein called 12-Lipoxygenase. He believed the program was ready to be brought into a company, and there was potential for broad therapeutic utility of the inhibitor, which was intriguing. I have heard a lot of drug program pitches and usually get a sense of where the holes are pretty quickly. In this case, we talked for 30 minutes and afterward I knew this program was ready for company formation. Our first product in development, VLX-1005, is for treatment of the rare blood disorder heparin-induced thrombocytopenia & thrombosis (HITT) which also happens to be the same blood disorder that nearly killed my father years ago. We started the company in 2017 along with Daves colleague from the NCATS (National Center for Advancing Translational Sciences) at the NIH, Matt Boxer, with our rare disease blood disorder drug as our lead candidate. I feel the stars really aligned for us and we have been charging ahead ever since.
Dave, in collaboration with several other partners, led the development of our lead candidate, VLX-1005 while he was a chemistry Group Leader at NCATS.
What is your life science background and what did you do prior to co-founding Veralox?
I hold a Ph.D. in Human Genetics from the University of Maryland School of Medicine. I then went on to be a clinical cytogenetics fellow at the National Cancer Institute Department of Pathology at the NIH. While at NIH I developed a drug target ID platform that got the interest of companies doing cancer drug discovery and I eventually joined a company called Avalon, where I worked in drug discovery and development for about 9 years and served my last two years as Head of Translational Oncology. I learned a great deal about the drug discovery and development process during my time there.
After Avalon I was part of a group of local life science veterans that co-founded the Clinical Research Organization (CRO) Noble Life Sciences. The CRO also served as a kind of incubator for new companies. We incubated several new companies like Neximmune and Convergene Pharmaceuticals, where I served as Chief Scientific Officer and President from 2011 to 2015 before taking on the Chief Executive role from 2015 to 2017. During that time I had met and worked with Dave and I left Convergene to start Veralox with him and our other co-founder Matthew Boxer.
What is Veraloxs lead drug candidate, what disease does it target and where does it sit in the development process?
Our lead drug candidate is for the treatment of patients with HITT, which is a rare, life-threatening disease caused by an immune reaction to Heparin. This drug candidate is a small molecule product that inhibits the 12-lipoxygenase (12-LOX) enzyme which produces 12-HETE. Both 12-LOX and 12-HETE are implicated in numerous diseases. The only FDA-approved drug for HIT/HITT, argatroban, doesnt treat the underlying cause of the disease and has significant potential side effects leaving a significant unmet need.
There are approximately 50,000 people that will be diagnosed with HIT/HITT in the US this year but the number of those treated for this disease is approximately 150,000 annually. HIT takes time to diagnose and doctors cant wait for a definitive diagnosis to make treatment decisions. If patients are suspected of having the disease they must be treated immediately given the risk for deadly thrombosis. The current approved treatment, argatroban, can cause major bleeds which in and of itself can lead to death in these patients. Better drugs are needed that address the pathology of the disease without contributing potentially lethal side effects.
Our HIT treatment inhibits the underlying pathophysiology of HITT to halt the aberrant immune response driving the disease and essentially offering the potential of a curative modality.
Weve been strategically focused on HIT/HITT, but our approach has potential for a number of other indications. For our HIT/HITT drug candidate, weve submitted our Orphan Drug application and our pre-IND (Investigational New Drug) briefing book to the FDA; we expect to have our GMP material soon and to start GLP toxicology studies in the second quarter of this year. Our team expects to submit the IND for our lead candidate by the end of 2020. We are also co-developing a small molecule, orally administered drug product. We plan to advance this candidate for the treatment for Type 1 Diabetes, which is about a year behind our HIT/HITT clinical candidate.
What are some recent Veralox funding milestones and what are the companys next funding steps?
Weve had success raising capital from grants and venture capital groups. Veralox received about 300K from NIHs Small Business Innovation Research (SBIR) Fund, Phase I, and $300K from NIHs Small Business Technology Transfer (STTR) Fund. We also recently closed a $5.4M seed round that was co-led by Sanofi Ventures and the JDRF T1D Fund and included participation from the VTC Innovation and VTC Seed Fund, the Maryland Momentum Fund, the University of Vermont Health Network and TEDCO.
We are currently raising Series A funding to support clinical development of VLX-1005 for HITT and advance our second drug product for treatment of Type 1 Diabetes into clinical trials. Weve initiated discussions with several large venture capital firms all of which could lead our funding round and have the full support of our current investors in the process.
What can you tell us about your experience at FITCI and as a startup in the Frederick life science ecosystem?
Ive had experiences with other incubators, some of which no longer exist, but theres no comparison to FITCI. They offer great support to emerging companies that desperately need it at the early stages. I have been at other incubators that give you a physical place to do business, but FITCI really keeps an eye on you. The FITCI team helps you solve problems and they offer quarterly meetings for the CEOs to meet with groups of successful business people who can offer advice and provide mentorship for those in need. These mentors might not be in therapeutics but theyve done this before and can really help.
I really love Frederick because, to me, the area is just like a startup. Its really going somewhere. FITCI has two locations, but whenever we meet with people, we use the Market Street location in downtown Frederick. Its a nice face to show off to people from outside of the area. Our time at FITCI is nearing its end because of our funding success, but when we graduate from the incubator, the plan is to stay in Frederick. Weve already been looking at a few places.
What are some near term challenges for Veralox and where do you see the company being in three to five years?
Our biggest challenge is developing a completely novel first-in-class product. Theres no blueprint or recipe one can exactly follow, and it is challenging. This is, however, what the Veralox team is trained to do and we are well prepared and excited by the challenge and promise of developing a new treatment that can drastically improve and perhaps save the lives of people suffering from a terrible disease.
Were also currently looking to hire a Chief Medical Officer soon. Finding the best talent is always a challenge, but I know well be able to find the right person.
In three to five years, our goal is to have several products in the clinic and possibly an approved HIT/HITT drug on the market. Veralox has the potential to become an anchor life science company in the region. But for now, Id like Veralox to be known as the company that did what they said theyd do were community-minded and will continue to work hard to make a difference in the lives of patients with debilitating diseases.
Steve has over 20 years experience in copywriting, developing brand messaging and creating marketing strategies across a wide range of industries, including the biopharmaceutical, senior living, commercial real estate, IT and renewable energy sectors, among others. He is currently the Principal/Owner of StoryCore, a Frederick, Maryland-based content creation and execution consultancy focused on telling the unique stories of Maryland organizations.
See the original post here:
- How to use precision medicine to personalize COVID-19 treatment according to the patients genes - TheStreet - September 2nd, 2020
- Meiotic chromosome synapsis depends on multivalent SYCE1-SIX6OS1 interactions that are disrupted in cases of human infertility - Science Advances - September 2nd, 2020
- Thought to Be Extinct, New Guinea's Singing Dogs Found Alive in the Wild - Smithsonian Magazine - September 2nd, 2020
- Humans have had mystery DNA for 300,000 yearsand now we might finally know what it is - SYFY WIRE - August 10th, 2020
- The Secret to a Long, Healthy Life Is in the Genes of the Oldest Humans Alive - Singularity Hub - August 10th, 2020
- LogicBio Therapeutics Reports Second Quarter 2020 Financial Results and Provides Business UpdatesFDA Clears IND Application for LB-001 for the... - August 10th, 2020
- Research on Tasmanian devil offers new insights into tackling human cancer - National Science Foundation - August 10th, 2020
- Human Genetics Market 2020 Size by Product Analysis, Application, End-Users, Regional Outlook, Competitive Strategies and Forecast to 2027 - Owned - August 10th, 2020
- University of Texas researchers find mutation that led to 2015-2016 Zika outbreak - Homeland Preparedness News - August 10th, 2020
- Blood lipid levels may be altered in some autistic people - Spectrum - August 10th, 2020
- NIH taps Dr. Lindsey Criswell as director of the National Institute of Arthritis and Musculoskeletal and Skin Diseases - National Institutes of Health - August 10th, 2020
- 'Hyper urban' coyote genomes are growing apart from their city and rural cousins - Massive Science - August 10th, 2020
- Why scientists are worried about a 'Warp Speed' COVID-19 vaccine - New Haven Register - August 10th, 2020
- Gyroscope Announces Appointment of Leaders in Retinal Disease, Gene Therapy and the Complement System to Its Clinical and Scientific Advisory Boards -... - August 10th, 2020
- Noel Rose, Who Demonstrated Autoimmunity Exists, Dies at 92 - The Scientist - August 10th, 2020
- Invasion of the Body Snatchers: Viruses Can Steal Our Genetic Code to Create New Human-Virus Genes - SciTechDaily - August 10th, 2020
- Why Are Only 10% of People Left-Handed? Here's What Scientists Know So Far - ScienceAlert - August 10th, 2020
- Holder pasteurization of donated human milk is effective in inactivating SARS-CoV-2 - CMAJ - August 10th, 2020
- Dinosaur diagnosed with bone cancer that afflicts humans today - CNN - August 10th, 2020
- LogicBio Therapeutics Reports Second Quarter 2020 Financial Results and Provides Business Updates - GlobeNewswire - August 10th, 2020
- The Secret to Healthy Longevity Is in the Genes of the Oldest Humans Alive - Singularity Hub - August 10th, 2020
- BU's COVID-19 Testing Passes Its First Test | BU Today - BU Today - August 10th, 2020
- COVID-19 in Africa: Dampening the storm? - Science - August 10th, 2020
- Pacific Biosciences and Asuragen Collaborate to Develop Assays for Carrier Screening and other Applications Based on SMRT Sequencing Technology and... - August 10th, 2020
- U of T researchers identify molecular switch allowing parasites to survive inside hosts without oxygen - News@UofT - August 9th, 2020
- LUMINEX : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q) - marketscreener.com - August 8th, 2020
- Gaucher Disease Treatment Market Size, Top Companies, Trends, Growth Factors Details by Regions, Types and Applications - Owned - August 8th, 2020
- How studying genetics and lifestyle can shape a healthier MENA region - The European Sting - August 8th, 2020
- Detection of H1 Swine Influenza A Virus Antibodies in Human Serum Samples by Age Group - CDC - August 7th, 2020
- UW researchers devise approach to treat rare, incurable form of blindness - University of Wisconsin-Madison - August 7th, 2020
- Prevail Therapeutics to Present at 2020 Wedbush PacGrow Healthcare Conference - Stockhouse - August 7th, 2020
- human genetics | Description, Chromosomes, & Inheritance ... - August 6th, 2020
- Human Genetics | Pitt Public Health | University of Pittsburgh - August 6th, 2020
- Triplet Therapeutics To Present at Upcoming Events - Business Wire - August 5th, 2020
- 'Hyper urban' coyote genomes are growing apart their from city and rural cousins - Massive Science - August 5th, 2020
- Baylor genomics teams partner to provide COVID-19 testing for Houston area - Baylor College of Medicine News - August 5th, 2020
- Gaucher Disease Treatment Market (Impact of COVID-19) Top Growing Companies: Acetelion Pharmaceutical (J&J Ltd.), Erad Therapeutic Inc., JCR... - August 5th, 2020
- High-fat Diet and Genetics Lead to Anxiety and Depression in Rats - Newswise - August 5th, 2020
- 'Mono' virus turns on cancer-related genes. Here's how. - Live Science - August 4th, 2020
- Human Challenge Trial Neither Essential Nor Ethically Justified at This Time, Says US Expert Anthony Fauci - Yahoo India News - August 4th, 2020
- ICMR to host global web conference on science, ethics of COVID-19 vaccine starting 4.30 pm today - Firstpost - August 4th, 2020
- Faculty/staff honors: Women in engineering network nod, winning magazine article on geologic hazards and refugees and two national genetics society... - July 31st, 2020
- ENCODE3: Interpreting the human and mouse genomes - Science Codex - July 31st, 2020
- Revealing the intrinsic functioning of human and mouse genomes - Tech Explorist - July 31st, 2020
- Maternal Immune Activation Causes Schizophrenia-like Behaviors in the Offspring through Activation of Immune-Inflammatory, Oxidative and Apoptotic... - July 31st, 2020
- Podcast: The ancient war between genes and disease - Genetic Literacy Project - July 31st, 2020
- Pitt's School of Public Health welcomes students with opera about obstetrician who championed hand-washing - TribLIVE - July 31st, 2020
- BNGO Stock Price: BioNano Genomics Inc. retreats, starts week in the red - FXStreet - July 31st, 2020
- A Genetic Mutation Reveals How the SARS-CoV-2 Virus Strikes - Technology Networks - July 31st, 2020
- 88-Year Old Daniel Smith, Son Of Slave, Tells His Story - Moguldom - July 31st, 2020
- 23andMe Releases Devastating Analysis of Trans-Atlantic Slave Trade - Futurism - July 31st, 2020
- MSU researcher earns grant to study effects of droughts - MSUToday - July 31st, 2020
- Massive Growth in Human Genetics Market Breaking new grounds and touch new level in Upcoming Year by QIAGEN, Agilent Technologies, Thermo Fisher... - July 30th, 2020
- CEO of genome analysis firm: We have the data to prove people will take care of themselves - University of Miami - July 30th, 2020
- Researchers from U of T, Harvard study collective human behaviour amid COVID-19 - News@UofT - July 30th, 2020
- Gene mutations discovered as a trigger for male infertility - BioNews - July 29th, 2020
- Cerevel Therapeutics and Cyclica Announce Research Collaboration to Use Artificial Intelligence to Accelerate Discovery of Novel Medicines in... - July 29th, 2020
- Relatives of coronavirus may have been in bats for decades - Opelika Auburn News - July 29th, 2020
- Link between platelets and Covid-19 virus? - The New Indian Express - July 29th, 2020
- Fortress Biotech Announces Publication of Study on Targeted Next Generation Sequencing for Newborn Screening of Menkes Disease in Molecular Genetics... - July 29th, 2020
- New 23andMe Study Reveals the Genetic Legacy of Slavery in the Americas - Gizmodo - July 29th, 2020
- The Groundbreaking Scientist Who Risked All in Pursuit of His Beliefs - The New York Times - July 29th, 2020
- 23andMe and GSK Head to Clinical Trials With Cancer Drug - MSN Money - July 29th, 2020
- Human Genetics - David Geffen School of Medicine at UCLA - July 29th, 2020
- Discovering how genetic 'dark matter' plays a role in mental illness is just the tip of the iceberg for human health - The Conversation UK - July 29th, 2020
- Prevail Therapeutics Granted Composition of Matter Patent for Experimental Gene Therapy Program PR006 - GlobeNewswire - July 29th, 2020
- The toll of shrinking jaws on human health | Stanford News - Stanford University News - July 28th, 2020
- Global Hereditary Genetic Testing Market (2020 to 2030) - Analysis and Forecast - GlobeNewswire - July 28th, 2020
- Triplet Therapeutics nabs Scholar Rock R&D exec as new CSO - FierceBiotech - July 27th, 2020
- Meet Dr Sarah Gilbert, one of the scientists leading the race to find a coronavirus vaccine - The Indian Express - July 27th, 2020
- Genetic basis of bats superpowers revealed - KLBK | KAMC | EverythingLubbock.com - July 27th, 2020
- Study of Gene's Hormone Effects Leads to Surprise Insight into Pituitary Tumors - University of Michigan Health System News - July 26th, 2020
- Dutch University hospital Radboudumc finds genetic mutation as a reason for lack of defense against corona - Innovation Origins - July 26th, 2020
- Tailoring Depression Treatment With Genetics - Technology Networks - July 26th, 2020
- Genetic puzzle: How mice can be modified to help in the race to develop coronavirus therapies - Genetic Literacy Project - July 26th, 2020
- The genetic basis of bats' superpowers revealed - Newswise - July 26th, 2020
- Inside the Global Quest to Trace the Origins of COVID-19and Predict Where It Will Go Next - TIME - July 26th, 2020
- Baylor Genetics and the City of Houston Form COVID-19 Testing Partnership - PRNewswire - July 25th, 2020
- Triplet Therapeutics Appoints Alan Buckler, Ph.D., as Chief Scientific Officer - Business Wire - July 25th, 2020
- The genetic basis of bats superpowers revealed - YubaNet - July 25th, 2020